Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Hero Section Background Image

Publications

Access Travere’s peer-reviewed publications.

Long-Term Outcomes in IgA Nephropathy
Publication NephrologyIgAN

Long-Term Outcomes in IgA Nephropathy

Clinical Journal of the American Society of Nephrology – 2023

Data from the UK National Registry of Rare Kidney Diseases (RaDaR) IgA nephropathy cohort highlight poor long-term outcomes for patients. Read more.

View summary

MA-DS-25-0105 | October 2025

Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward in Light of the PARASOL Initiative
Publication NephrologyFSGS

Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward in Light of the PARASOL Initiative

Future Rare Diseases – 2025

This commentary reflects on the DUPLEX trial results and examines the PARASOL initiative in validating proteinuria as a surrogate endpoint in FSGS clinical trials.

View summary

MA-SP-25-0089 | January 2026

Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial
Publication NephrologyFSGS

Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial

Clinical Journal of the American Society of Nephrology – 2025

A post hoc analysis of the Phase 3 DUPLEX trial assessed the antiproteinuric effect of sparsentan compared with irbesartan in patients with genetic-associated FSGS.

View summary

MA-SP-26-0009 | March 2026

All our publications

Filter by:

Year

Year

×
Clear All

Therapeutic area

Therapeutic area

×
Clear All

Disease area

Disease area

×
Clear All

Product

Product

×
Clear All

Study/Registry

Study/Registry

×
Clear All

Study type

Study type

×
Clear All

Resource type

Resource type

×
Clear All
Clear All

Filter by:

Year

Year

×
Clear All

Therapeutic area

Therapeutic area

×
Clear All

Disease area

Disease area

×
Clear All

Product

Product

×
Clear All

Study/Registry

Study/Registry

×
Clear All

Study type

Study type

×
Clear All

Resource type

Resource type

×
Clear All

Results55

Sort by

Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial
Publication NephrologyFSGS

Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial

Clinical Journal of the American Society of Nephrology – 2025

Read more
Lived Experiences of Patients and Care Providers in Focal Segmental Glomerular Sclerosis and IgA Nephropathy
Publication NephrologyFSGSIgAN

Lived Experiences of Patients and Care Providers in Focal Segmental Glomerular Sclerosis and IgA Nephropathy

Glomerular Diseases – 2025

Read more
Publication NephrologyFSGSIgAN

Targeting Endothelin and Angiotensin Pathways for Kidney Function Preservation in Glomerular Disease

European Medical Journal – 2026

Read more
Publication NephrologyIgAN

Association Between Complete Proteinuria Remission and Kidney Function in Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy

Clinical Journal of the American Society of Nephrology – 2025

Read more
KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)
Publication NephrologyIgAN

KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)

Kidney International – 2025

Not funded by Travere

Read more
Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis
Publication NephrologyFSGS

Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis

Kidney Medicine – 2022

Read more
Load more

The publications featured on this page have been partially or fully funded by Travere Therapeutics, Inc., unless noted otherwise. For more information, please refer to the publication.

MSL CTA Image

Connect with our MSL team today

Arrange a meeting with a member of our medical science liaison (MSL) team to discuss the latest insights, clinical trial data, and management trends.

Find your MSL